2016
DOI: 10.1001/jama.2016.5504
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Early Prophylactic High-Dose Recombinant Human Erythropoietin in Very Preterm Infants on Neurodevelopmental Outcome at 2 Years

Abstract: ; for the the Swiss EPO Neuroprotection Trial Group IMPORTANCE Very preterm infants are at risk of developing encephalopathy of prematurity and long-term neurodevelopmental delay. Erythropoietin treatment is neuroprotective in animal experimental and human clinical studies. OBJECTIVE To determine whether prophylactic early high-dose recombinant human erythropoietin (rhEPO) in preterm infants improves neurodevelopmental outcome at 2 years' corrected age. DESIGN, SETTING, AND PARTICIPANTS Preterm infants born be… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
87
3
11

Year Published

2016
2016
2022
2022

Publication Types

Select...
10

Relationship

3
7

Authors

Journals

citations
Cited by 121 publications
(109 citation statements)
references
References 37 publications
1
87
3
11
Order By: Relevance
“…Indeed, an association of age with the severity of injury has shown mixed results in human studies. In a recent study of early prophylactic high-dose EPO in very preterm infants, there were no statistically significant differences in neurodevelopmental outcomes at 2 years, despite positive changes in MRI at earlier ages between the placebo- and EPO-treated groups [38]. …”
Section: Discussionmentioning
confidence: 99%
“…Indeed, an association of age with the severity of injury has shown mixed results in human studies. In a recent study of early prophylactic high-dose EPO in very preterm infants, there were no statistically significant differences in neurodevelopmental outcomes at 2 years, despite positive changes in MRI at earlier ages between the placebo- and EPO-treated groups [38]. …”
Section: Discussionmentioning
confidence: 99%
“…We believe that early EPO administration is necessary to target pathways of VIBI and prevent injury manifestation. However, the only clinical trial in which preterm infants were administered the first dose of high-dose EPO within the first 3 h of birth has presented discouraging 2-year follow-up results showing no differences in neurodevelopmental outcomes between EPO and placebo groups [52] . Indeed, the therapeutic time window of EPO administration needs to be ascertained before the full neuroprotective potential of EPO for VIBI can be established.…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, rEpo application seems to improve white matter integrity (assessed by MRI) and neurocognitive outcomes (in retrospective and prospective investigations) [147,148,[150][151][152][153] . Other studies did not reveal any positive effects of rEpo therapy [154] . This might again be due to different doses and application regimes, ranging from high-dose application for a few days to lower doses for several weeks.…”
Section: Hormonesmentioning
confidence: 84%